Insider Transactions in Q1 2022 at Atara Biotherapeutics, Inc. (ATRA)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 01
2022
|
Amar Murugan EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,577
-0.93%
|
$23,193
$9.86 P/Share
|
|
Mar 01
2022
|
Amar Murugan EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,814
+27.08%
|
-
|
|
Mar 01
2022
|
Pascal Touchon President and CEO |
SELL
Open market or private sale
|
Direct |
8,828
-1.73%
|
$79,452
$9.86 P/Share
|
|
Mar 01
2022
|
Pascal Touchon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
180,565
+26.18%
|
-
|
|
Mar 01
2022
|
Kristin Yarema Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,533
+20.99%
|
-
|
|
Mar 01
2022
|
Jakob Dupont EVP, Head of R&D |
SELL
Open market or private sale
|
Direct |
2,221
-1.31%
|
$19,989
$9.86 P/Share
|
|
Mar 01
2022
|
Jakob Dupont EVP, Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
78,506
+31.71%
|
-
|
|
Mar 01
2022
|
Utpal Koppikar Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,763
-0.87%
|
$33,867
$9.86 P/Share
|
|
Mar 01
2022
|
Utpal Koppikar Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,235
+22.01%
|
-
|
|
Feb 10
2022
|
Jakob Dupont EVP, Head of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-5.23%
|
$80,000
$16.0 P/Share
|
|
Feb 10
2022
|
Jakob Dupont EVP, Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.97%
|
$45,000
$9.58 P/Share
|
|
Feb 07
2022
|
Utpal Koppikar Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,496
-1.58%
|
$34,944
$14.46 P/Share
|
|
Jan 03
2022
|
Jakob Dupont EVP, Head of R&D |
SELL
Open market or private sale
|
Direct |
5,000
-5.23%
|
$80,000
$16.01 P/Share
|
|
Jan 03
2022
|
Jakob Dupont EVP, Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.97%
|
$45,000
$9.58 P/Share
|